CL2021003317A1 - Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelícula. - Google Patents

Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelícula.

Info

Publication number
CL2021003317A1
CL2021003317A1 CL2021003317A CL2021003317A CL2021003317A1 CL 2021003317 A1 CL2021003317 A1 CL 2021003317A1 CL 2021003317 A CL2021003317 A CL 2021003317A CL 2021003317 A CL2021003317 A CL 2021003317A CL 2021003317 A1 CL2021003317 A1 CL 2021003317A1
Authority
CL
Chile
Prior art keywords
bacterial infections
biofilm
medication
infections involving
treat bacterial
Prior art date
Application number
CL2021003317A
Other languages
English (en)
Inventor
Justyna Nowakowska
Grégoire Vuagniaux
Kadi Linda
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of CL2021003317A1 publication Critical patent/CL2021003317A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere al uso de Afabicina en un método de tratamiento de infecciones bacterianas que involucran biopelículas que contienen bacterias de staphylococcus, en donde el método comprende administrar al paciente Afabicina en combinación con al menos un agente adicional seleccionado entre lipopéptidos, glicopéptidos, y lincosamidas, tales como Daptomicina, y/o Vancomicina.
CL2021003317A 2019-06-14 2021-12-13 Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelícula. CL2021003317A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19180281 2019-06-14

Publications (1)

Publication Number Publication Date
CL2021003317A1 true CL2021003317A1 (es) 2022-09-20

Family

ID=66867028

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003317A CL2021003317A1 (es) 2019-06-14 2021-12-13 Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelícula.

Country Status (15)

Country Link
US (1) US20230126947A1 (es)
EP (1) EP3982975A1 (es)
JP (1) JP7418475B2 (es)
KR (1) KR20220020963A (es)
CN (1) CN113939306A (es)
AU (1) AU2020293635A1 (es)
BR (1) BR112021025306A8 (es)
CA (1) CA3139942A1 (es)
CL (1) CL2021003317A1 (es)
EA (1) EA202290048A1 (es)
IL (1) IL288861A (es)
MA (1) MA56184A (es)
MX (1) MX2021015513A (es)
SG (1) SG11202113174SA (es)
WO (1) WO2020249731A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003673B2 (en) * 2005-05-31 2011-08-23 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
NZ702695A (en) 2012-06-19 2015-10-30 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
FR3017294B1 (fr) 2014-02-07 2021-10-01 Atlangram Nanoparticules lipidiques comprenant un antibiotique et leurs utilisations en therapie
US10751351B2 (en) * 2016-02-26 2020-08-25 Debiopharm International S.A. Medicament for treatment of diabetic foot infections

Also Published As

Publication number Publication date
KR20220020963A (ko) 2022-02-21
MX2021015513A (es) 2022-04-20
JP2022535598A (ja) 2022-08-09
MA56184A (fr) 2022-04-20
IL288861A (en) 2022-02-01
BR112021025306A8 (pt) 2022-09-20
US20230126947A1 (en) 2023-04-27
EA202290048A1 (ru) 2022-03-10
WO2020249731A1 (en) 2020-12-17
SG11202113174SA (en) 2021-12-30
EP3982975A1 (en) 2022-04-20
BR112021025306A2 (pt) 2022-02-01
AU2020293635A1 (en) 2022-01-27
CN113939306A (zh) 2022-01-14
JP7418475B2 (ja) 2024-01-19
CA3139942A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
BR112017028413A2 (pt) peptídeos antimicrobianos estabilizados
ES2523968T3 (es) Terapia de combinación antibacteriana para el tratamiento de infecciones por bacterias Gram-positivas
ECSP18017254A (es) Composiciones con potenciadores de permeación para suministro de fármacos
EP2494059A4 (en) USE OF METHYSULFONYLMETHANE (MSM) FOR MODULATION OF MICROBIAL ACTIVITY
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
CL2014000592A1 (es) Composicion oftalmica de administracion topica que comprende povidona-yodo, esteroide, anestesico, reforzador de la penetracion, preservativo antimicrobiano, cosolvente/surfactante y agente de aumento de la viscosidad; y metodo de tratamiento y/o profilaxis de un trastorno oftalmico o una infeccion por microorganismos en el ojo.
BR112017006526A2 (pt) composição e kits para inibição de infecção microbiana patogênica e métodos de usar os mesmos
BR112014027842A2 (pt) bacteriófago lisina e combinações de antibióticos contra bactérias gram-positivas
SG10201811361XA (en) Treatment of polybacterials infections
BR112017019413A2 (pt) combinação de agente bactericida com um agente alcalinizante lisossomotrópico para o tratamento de uma infecção bacteriana
BR112017022768A2 (pt) desinfecção de tecido com ondas de choque de pressão acústica
MX2015016319A (es) Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112022012514A2 (pt) Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas
EA201890633A1 (ru) Композиции и способы для многофункциональных растворов для дезинфекции и стерилизации
MX2023004188A (es) Compuestos fosfolipidos y usos de estos.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2020000249A (es) Composiciones antimicrobianas efectivas contra bacterias y hongos.
WO2016004216A3 (en) Hydrogels for treating and ameliorating infections and methods of making and using them
MA39955A (fr) Compositions désinfectantes et antimicrobiennes, en particulier pour le domaine vétérinaire
CL2021003317A1 (es) Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelícula.
CO2021015696A2 (es) Combinación de compuestos activos
CL2021001141A1 (es) Composiciones para el tratamiento de biopelículas sin inducir resistencia antimicrobiana
CO2023013406A2 (es) Análogos de rifamicina en combinación con vancomicina y usos de los mismos